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Abstract
Background: Quantification of hepatotocyte death is useful to evaluate the progression of alcoholic liver diseases. Our aims
were to quantify and correlate the circulating levels of Cytokeratin 18 (CK18) and its caspases-generated fragment to disease
severity in heavy alcoholics.
Methodology/Principal Findings: CK18 and CK18-fragment were evaluated in the serum of 143 heavy alcoholics. Serum
levels of markers of hepatocyte death (CK18), apoptosis (CK18 fragment) and necrosis (CK18 -CK18 fragment) increased in
patients with severe fibrosis compared to patients with mild fibrosis. These markers strongly correlated with Mallory-Denk
bodies, hepatocyte ballooning, fibrosis and with hepatic TNFa and TGFb assessed in the liver of 24 patients. Elevated levels
of serum hepatocyte death and apoptotic markers were independent risk factors in predicting severe fibrosis in a model
combining alkaline phosphatase, bilirubin, prothrombin index, hyaluronate, hepatocyte death and apoptotic markers. The
level of markers of hepatocyte death and apoptosis had an area under the receiving operator curve that predicted severe
fibrosis of 0.84 and 0.76, respectively.
Conclusion/Significance: Death of hepatocytes can be easily evaluated with serum markers and correlated with severe
fibrosis in heavy alcohol drinkers. These biomarkers could be useful to rapidly evaluate liver injuries and the efficacy of
therapies.
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Introduction
Excessive alcohol consumption is the third leading preventable
cause of death in the United States [1]. Regular alcohol use can
result in hepatic steatosis, which eventually progresses to
steatohepatitis, fibrosis and cirrhosis. Up to 40% of patients with
severe acute alcoholic hepatitis die within six months [1]. A large
body of evidence suggests that apoptosis of hepatocytes may be a
key mechanism of alcohol-induced liver injury [2,3]. It has been
largely reported that apoptosis of hepatocytes is a significant
histological feature of human Alcoholic Liver Diseases (ALD). The
magnitude of apoptosis evaluated by the Tunel assay, caspase
activation and the apoptotic index correlated with the severity of
ALD, the degree of inflammation and stage of fibrosis [2].
Hepatocyte apoptosis is more pronounced in patients with high
bilirubin and AST levels [2]. Death receptors (i.e. TNFa/TNFa
Receptor, Fas-L/Fas), oxidative and endoplasmic reticulum stress,
glutathione depletion could play an important role in alcohol
induced apoptosis of hepatocytes [2,3]. Elevated circulating levels
of soluble Fas, Fas ligand and TNFa have been reported [4,5],
together with upregulation of the receptors in patients with ALD
[6,7,8]. When the activation of mitochondrial-dependent apopto-
sis was more severe and involved most of the mitochondria, ATP
was depleted and could result in a switch from apoptosis to
necrosis [9]. Cytokeratin 18 (CK18) is the major intermediate
filament protein in the liver and one of the most prominent
substrates of caspases during apoptosis of hepatocytes [10].
Caspases-generated CK18 fragments are released from the tissue
and are resistant to proteolysis [11,12]. CK18 is cleaved by
caspases at two sites (Asp238 and Asp396) and the M30 antibody
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17599recognizes the neo-epitope mapped to positions 387 to 396, which
is only revealed after caspase cleavage. The M30-based ELISA
thus determines the circulating levels of a specific caspases-
generated CK18 fragment and is proposed as a surrogate
biomarker of cell apoptosis [11]. The M65-based ELISA
determines the circulating levels of both the caspases-generated
fragment and intact CK18. The soluble full-length CK18 is
released from cells undergoing necrosis [11,12]. These markers
have been evaluated in patients with different chronic liver
diseases including alcoholic and nonalcoholic fatty liver diseases
[13]. The CK18 fragment level appears to be a noninvasive
biomarker for nonalcohololic steatohepatitis [14,15,16,17] and
changes in the level correlate with changes in the NAFLD activity
score [18]. In contrast, few studies have been performed on
patients with ALD. The level of CK18 or of the CK18 fragment
was frequently increased in small groups of alcoholics and may act
as a marker of hepatitis [19,20,21]. The serum levels of total CK18
in heavy drinkers (n=15) were higher than those of healthy
controls (n=10), and even tended to be higher than those of
patients with biopsy-proven malignancy of epithelial origin
(n=22) including adenocarcinoma of a variety of origins, small
lung carcinoma, hypernephroma and epidermoid easophageal
carcinoma [22]. The same group showed that serum levels of total
CK18 correlated with the apoptotic score in 53 patients (31 with
alcoholic hepatitis and 22 with fatty liver) [19]. More recently, it
has been reported that serum levels of CK-18 fragment in patients
with alcoholic hepatitis (n=50) were higher than those of healthy
controls (n=50) and heavy drinkers (n=50), and even tended to
be higher than those of patients with malignancy (n=50) [21].
In this study, we focused on the death of hepatocytes by
apoptosis and/or necrosis as evaluated by circulating serum
biomarkers in a cohort of 143 patients with ALD and investigated
correlation with disease severity. The prediction of severe fibrosis
based on these markers was also evaluated.
Materials and Methods
Study population
From October 1997 to June 1998, 143 consecutive heavy
alcohol drinkers (105 men, 38 women, mean age: 4869 years)
admitted to our Liver unit for detoxification and/or in patient
rehabilitation were entered into this study. All patients had
consumed over 80 g ethanol per day for more than 5 years. All
patients were negative for circulating hepatitis B surface antigen,
hepatitis C virus, and human immunodeficiency virus. No patient
had osteoarthritis or rheumatoid arthritis. Fasting blood samples
were used to measure alanine amino transferase (ALT), aspartate
aminotransferase (AST) and gamma glutamyl transferase (cGT). A
needle liver biopsy was performed on all patients by the
transparietal approach. Biopsies were processed routinely and
stained with hematoxylin-eosin-safran and Sirius Red. The length
of the liver biopsy was over 15 mm. Histopathological features
were semi-quantitatively evaluated: grade of steatosis (0, ,5%; 1,
5%–30%; 2, .30%–60%; 3, .60%); hepatocellular ballooning (0,
none; 1, few balloon cells; 2, many cells/prominent ballooning);
megamitochondria (0, none to rare; 1, many); Mallory’s hyaline (0,
none to rare; 1, many) and fibrosis stage (From 0, none, to 4,
cirrhosis). The grading of hepatic activity was done according to
the Activity score of Orrego et al. [23]. The characteristics of
whole cohort from which a representative group of 24 alcoholic
patients was selected for the hepatic gene expression analysis are
described in Table 1. Sera and liver tissues were stored at 280uC
until use. These patients were included later in the ‘‘Fibroscore
program’’. All subjects gave their informed written consent to
participate in this research study according to French legislation
regarding Ethic and Human Research (Huriet-Serusclat law, the
‘‘Comite ´ Consultatif de Protection des Personnes dans la
Recherche Biome ´dicale de Nice’’ approved this study, Nu03.613).
Circulating levels of total and fragmented CK18
Intact CK18 is released by necrotic cells. CK18 is also cleaved by
caspases during apoptosis, generating soluble protein fragments.
TheM65H ELISAassay,whichdetects allformsofCK18,measures
cell death due to both apoptosis and necrosis (CK18 intact and
fragment), while the M30 ApoptosenseH ELISA assay specifically
measuresapoptosis (the caspases-generatedCK18 fragment,CK18-
Asp396). The quantification of necrosis results from the difference
between total CK18 values (M65) and the values of the caspases-
generated fragment (M30). The caspases-generated CK18 fragment
(M30 antigen) and CK18 (M65 antigen) were evaluated in the
serum of 143 patients with M30 ApoptosenseH ELISA and M65H
ELISA kits (PEVIVA), respectively, as described by the manufac-
turer’s instructions. All samples were analyzed in duplicate, in
random order and blinded to the clinical/pathological data. For
boththeM30ApoptosenseHELISAandM65HELISA,withinassay
(WA % CV) variation was ,10% and between assay (BA % CV)
variation was ,10% for samples .100 U/L. The minimum
detectableconcentrationofM30and M65were25 U/Land11 U/
L, respectively. Cytokeratins are released into the circulation as
protein complexes. These complexes are remarkably stable during
sample collection and long-term storage. Furthermore, plasma/
serum samples can be exposed to repetitive freeze-thaw cycles
without loss of activity [24].
Table 1. Characteristics of Serum and Gene groups.
Serum group Gene group
N (female/male) 143 (38/105) 24(4/20)
Age (years) 48.0(42.0, 53.0) 48.0(46.0, 53.0)
Alcohol (g/day) 120.0(90.0, 182.5) 142.0(90.0, 170.0)
AST (IU/L) 66.0(41.0, 120.0) 52.0(32.0, 119.0)
ALT (IU/L) 41.0(25.0, 78.0) 39.0(23.0, 57.5)
AST/ALT 1.7(1.1, 2.5) 1.7(1.2, 2.6)






Inflammation (%) 22.9 16.7
Mallory-Denk body (%) 35.2 16.7







Data are expressed as Median (25th, 75th percentile) or %. AST: aspartate
amino-tranferase; ALT: alanine amino-transferase; cGT: Gamma Glutamyl
Transpeptidase.
doi:10.1371/journal.pone.0017599.t001
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Total RNA was extracted from human tissues using a RNeasy Mini
Kit (Qiagen, Contraboeuf, France). The samples were treated with
Turbo DNA-free
TM (Applied Biosystems, Contraboeuf, France)
following the manufacturer’s protocols. The quantity and quality of
the isolated RNA were determined using the Agilent 2100 Bioanalyser
with RNA 6000 Nano Kit (Agilent Technologies). Total RNA (0.5 mg)
was reverse-transcribed with the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA). Real-time
quantitative PCR was performed using the ABI PRISM 7500 Fast
Real Time PCR System and FAM
TM dyes (Applied Biosystems,
Contraboeuf, France) following the manufacturer’s protocols in
our Genomics facilities. The TaqManH gene expression assays
were purchased from Applied Biosystems: Fas-L, Hs00181225_m1;
TNFa, Hs00174128_m1; TGFb, Hs00171257_m1; and RPLP0;
Hs99999902_m1. Gene expression values were normalized to the
value of the housekeeping gene RPLP0 (Ribosomal Phosphoprotein
Large P0) and calculated based on the comparative cycle threshold Ct
method (2
2DDCt), as previously described [25,26]
Statistical analysis
Statistical significance of the differential circulating levels of the liver
markers of total hepatocyte death, apoptotis and necrosis in patients
with hepatic inflammation (A1) and severe fibrosis (F3/F4) compared
to patients with no inflammation (A0) and to moderate fibrosis (F0/1/
2), respectively, was determined using the non-parametric Mann-
Whitney test. P,0.05 was considered as significant. Correlations were
analyzed using the Spearman’s rank correlation test. Comparisons
were done using the Chi2 test or Fischer’s exact tests for nominal data
and by two-sample t tests for continuous data. Multivariate analyses
were performed using binary logistic regression with estimation of
odds ratios (OR) and 95% confidence intervals (95%CI). Diagnostic
performance was determined by constructing a ‘‘receiver-operating
characteristic’’ (ROC) curve and calculating the area under the ROC
(AUROC) curve for prediction of patients with advanced fibrosis
(F$3) for serum cell death markers. From these curves, the best cut-off
values were established for the serum cell death markers, which were
the values that maximized the sum of the sensitivity and specificity to
identify patient status. Statistical analyses were made using NCSS
2007 software.
Results
Elevated serum levels of total cell death, apoptotic and
necrotic biomarkers correlated with hepatic
inflammation, Mallory-Denk bodies, hepatocyte
ballooning and fibrosis
The goal of this study was to better characterize the hepatic
apoptosis and necrosis induced by chronic alcohol consumption.
To quantify liver cell death by apoptosis and/or necrosis in
alcoholic patients, we evaluated the circulating levels of biomark-
ers of cell death (soluble intact CK18 or the caspases-generated
CK18 fragment) in 143 alcoholic patients without or with hepatic
inflammation and with different grades of fibrosis (Table 1). As
shown in Figure 1, the circulating levels of the liver markers of
total hepatocyte death, apoptotis and necrosis were increased in
patients with hepatic inflammation (A1) and severe fibrosis (F3/F4)
compared to patients with no inflammation (A0) and to moderate
fibrosis (F0/1/2), respectively. Further, the three biomarkers
Figure 1. Elevated serum levels of total, apoptotic and necrotic
cell death markers in patients with hepatic inflammation and
advanced fibrosis. The serum of 143 alcoholic patients were used to
evaluate the circulating levels of total CK18 (M65H ELISA) and the
caspases-generated CK18 fragment (M30 ApoptosenseH ELISA). Results
were expressed as median (25
th,7 5
th percentile) in function to: (A)
hepatic inflammation (A1) and (B) advanced fibrosis (F3/4).
doi:10.1371/journal.pone.0017599.g001
Table 2. Correlation between circulating levels of total, apoptotic and necrotic cell death markers and hepatic inflammation,
Mallory-Denk bodies, ballooning and fibrosis in 143 alcoholic patients.
Marker of Inflammation Mallory-Denk bodies Ballooning Fibrosis
rs Pr s Pr s Pr s P
Cell death (CK18 total) 0.284 0.003 0.493 ,0.001 0.352 ,0.001 0.617 ,0.001
Apoptosis (CK18 fragment) 0.297 0.002 0.496 ,0.001 0.330 0.001 0.472 ,0.001
Necrosis (CK18 total-fragment) 0.238 0.012 0.426 ,0.001 0.316 0.001 0.594 ,0.001
Spearman’s rank correlation test.
doi:10.1371/journal.pone.0017599.t002
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bodies, ballooning and fibrosis (Table 2).
Elevated total cell death, apoptotic and necrotic markers
correlate with hepatic expression of TNFa and TGFb
In patients with ALD, liver apoptotic cell death and fibrosis
were reported to be associated with upregulation of TNFa, Fas-L
and TGFb, respectively [4,5,6,7,8,27]. So we evaluated the
expression of their mRNA level in the liver of 24 alcoholic
patients. As expected, the gene expression of TNFa, Fas-L and
TGFb was increased in patients with severe fibrosis (F3/F4)
compared with patients with no or mild fibrosis (F0/F1)(TNFa,
1.7460.27 vs 160.16, P=0.039; Fas-L, 1.5560.13 vs 160.11,
P=0.007; TGFb, 2.3360.17 vs 160.16, P=0.0001) and
correlated with the grade of fibrosis (Table 3). Furthermore, the
serum markers of total, apoptotic and necrotic cell death
correlated with hepatic expression of TNFa and TGFb (Table 3).
The serum total cell death and apoptotic markers were
independent risk factors in predicting severe liver fibrosis
in patients with alcoholic liver diseases
Since the circulating level of total cell death and apoptotic
markers was higher in patients with severe fibrosis (F3) compared
with patients with moderate fibrosis (F2) (data not shown), we
investigated the pertinence of the levels of serum total cell death
and apoptotic markers in predicting severe fibrosis. Using the
univariate analysis (Table 4), patients with advanced fibrosis (F$3)
were older with higher levels of total cell death, apoptotic and
necrotic markers, alkaline phosphatase, bilirubin and hyaluronate
levels and lower levels of platelets, albumin and of the
prothrombin index compared to patients with no to moderate
fibrosis (F,3) (Table 4). In contrast, the gender, the AST, ALT
and cGT levels were not associated with F$3. In a multivariate
analysis including total cell death and apoptotic markers, alkaline
phosphatase, bilirubin, prothrombin index and hyaluronate levels,
the only independent variables, when the judgment criterion was F
$3, were prothrombin index, hyaluronate, total and apoptotic cell
death markers (Table 5).
The three biomarkers of cell death accurately predicted
severe fibrosis in alcoholic patients
We then wanted to determine if these serum biomarkers could
predict severe fibrosis (F$3) in our cohort of 143 patients. As
shown in Figure 2, the area under the ROC curve (AUC) for
discriminating severe fibrosis with the total cell death, apoptotic or
necrotic markers was 0.84 (CI95% 0.76, 0.90), 0.76 (CI95% 0.66,
0.83) and 0.84 (CI95% 0.75, 0.89), respectively. The comparison
of the AUC indicated that the total cell death marker is
significantly different from the apoptotic marker (total cell death
marker AUROC versus apoptotic marker AUROC: P=0.0006;
total cell death marker AUROC versus necrotic marker AUROC:
P=0.73; apoptotic marker AUROC versus necrotic marker
AUROC: P=0.0505).
Several cut-off values were calculated for the levels of the three
markers for the prediction of F$3 in our cohort (Table 6). For
example, the cut-off point at 790 U/L of the cell death marker
predicted F$3 with a sensitivity of 84%, a specificity of 71%, a
Positive and Negative Predictive Value of 67.1% and 87.1%,
respectively. The cell death markers predicted severe fibrosis with
good specificity and sensitivity indicating that hepatic cell death
could be an important actor or characteristic of liver fibrosis
induced by chronic alcohol consumption.
Discussion
We report here that severe fibrosis associated with chronic
alcoholic liver disease correlated with substantial liver cell death
Table 3. Correlation between hepatic TGFb, TNFa and Fas-L gene expression and circulating levels of total, apoptotic and necrotic








rs Pr s Pr s Pr s P
TGFb 0.792 ,0.001 0.589 0.005 0.547 0.010 0.631 0.002
TNFa 0.489 0.034 0.519 0.019 0.504 0.033 0.529 0.016
Fas-L 0.577 0.008 0.359 0.120 0.347 0.134 0.283 0.226
The correlation between the expression levels of TGFb, TNFa and Fas-L mRNA (DCt) and circulating levels of biomarkers was analyzed using the Spearman’s rank
correlation test.
doi:10.1371/journal.pone.0017599.t003
Table 4. Univariate analysis of the 143 alcoholic patients
according to the severity of liver disease.
Data F,3 (n=85) F$3 (n=58) P
Age (years) 45.867.8 51.268.8 ,0.000001
Gender (female/male) 19/66 19/39 0.166613
Platelets (10
9/L) 204.0677.6 132.6676.2 ,0.000001
AST (IU/L) 90.46103.5 106.6681.6 0.453246
ALT (IU/L) 79.66175.3 41.4631.8 0.102965
cGT (IU/L) 302.26359.1 368.66391.1 0.296977
Alkaline phosphatase (IU/L) 88.8639.4 163.6689.8 ,0.000001
Bilirubin (mmol/L) 10.366.2 77.6693.9 ,0.000001
Albumin (g/L) 47.564.5 31.668.6 ,0.000001
Prothrombin index (%) 97.365.6 60.1620.3 ,0.000001
Total cell death marker (U/L) 669.66397.2 1392.26566.4 ,0.000001
Apoptotic marker (U/L) 381.66208.3 658.46305.2 ,0.000001
Necrotic marker (U/L) 294.76237.6 733.86335.6 ,0.000001
Hyaluronate (mg/L) 43.5631.3 486.16305.6 ,0.000001
Patients were classified as Fibrosis (F) ,3o r$3. Quantitative results are
expressed as means 6 standard deviations. AST: aspartate amino-tranferase;
ALT: alanine amino-transferase; cGT: Gamma Glutamyl Transpeptidase.
doi:10.1371/journal.pone.0017599.t004
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levels of cell death markers. These serum markers also correlated
with hepatic features of hepatocyte injury including ballooning
and the presence of Mallory-Denk bodies and hepatic expression
of TNFa and TGFb. Finally, we show that the total, apoptotic and
necrotic cell death markers accurately predict severe fibrosis in a
large cohort of alcoholic patients.
Markers of total, apoptotic and necrotic cell death correlated
with fibrosis and hepatic expression of TNFa and TGFb in our
patients. In agreement with our results, it has been shown that
apoptosis of hepatocytes was significantly increased in patients
with alcoholic hepatitis, and correlated with disease severity and
hepatic fibrosis [27]. It has been proposed that alcohol alters the
population of gut bacteria and inhibits intestinal motility, resulting
in overgrowth of a Gram-negative flora. Lipopolysaccharide is
elevated in portal blood and activates Kupffer cells leading to the
production of ROS and, consequently, TNFa. TNFa then
stimulates mitochondrial oxidant production in hepatocytes, which
are sensitized to apoptosis [28]. Hepatic apoptosis produces
chemokines and inflammation, which in turn may activate hepatic
stellate cells. Moreover, the phagocytosis of hepatocyte apoptotic
bodies by hepatic stellate cells and Kupffer cells enhances the
expression of pro-fibrogenic genes, such as TGFb, that may
initiate hepatic fibrosis [27]. Although the degradation of
cytokeratin during apoptosis is not completely understood, it has
been suggested that it could facilitate the formation of apoptotic
bodies and amplify the apoptotic signal [29]. We also showed that
necrosis of hepatocytes was enhanced in severe fibrosis and could
amplify these processes by massive release of cytokines.
Previous studies have shown that the serum levels of total CK18
(evaluated by a M3-based ELISA, the M3 antibody recognises
soluble fragments of CK18) in heavy drinkers (n=15) were higher
than those of healthy controls (n=10), and even tended to be
higher than those of patients with biopsy-proven malignancy of
epithelial origin (n=22) including adenocarcinoma of a variety of
origins, small lung carcinoma, hypernephroma and epidermoid
easophageal carcinoma [22]. The same group showed that serum
levels of total CK18 correlated with the apoptotic score in 53
patients (31 with alcoholic hepatitis and 22 with fatty liver) [19].
While these studies were done on a small group of patients, the
circulating level of total CK18 was increased in alcoholics. We
now reported that circulating levels of these cell death markers
correlated better with fibrosis than with the hepatic activity in a
large cohort of alcoholic patients (n=143).
We have shown for the first time that the serum cell death and
apoptotic markers were independent factors that predict severe
fibrosis in a large cohort of patients with ALD. Liver biopsy
remains the gold standard for assessment of liver fibrosis.
However, problems with liver biopsy include sampling error and
inter-observer variability. Fibroscan and the currently available
sero-algorithm tests (FibrotestH, FibrometerH) or the direct
biomarker (Hyaluronate) can differentiate between mild and
severe disease [30,31,32]. In the case of borderline results two or
more methods can be combined. However, identification of novel
markers is needed to improve sero-algorithm tests leading to
quantification of fibrosis and to monitor the dynamic nature of
fibrosis.
Cell death biomarkers have already been inserted into a
composite model for prediction of liver injury or patient survival in
other liver diseases. In acute liver failure, the cytokeratin 18-based
modification of the model for the End-Stage Liver Disease
(MELD) score improves prediction of spontaneous survival after
acute liver injury [33]. We have recently shown that the
association of serum CK18 fragments with ALT and the presence
of a metabolic syndrome in a composite model predicted hepatic
inflammation in morbidly obese patients [34]. These markers
could also be useful in rapidly providing information concerning
the treatment response. For example, the apoptotic cell death
(CK18 fragment) marker has been recently used to evaluate the
effect of some treatments in patients with chronic hepatitis C
infection [35,36].
In summary, circulating levels of total and the caspases-
generated fragment of cytokeratin 18 predict with good accuracy
severe fibrosis in heavy alcohol drinkers. These markers also
correlated with hepatocyte ballooning, the presence of Mallory-
Denk bodies and hepatic TNFa and TGFb expression. Further-
more, studies focusing on the behavior of these markers for the
follow up of patients with severe alcoholic liver disease should be of
great interest, particularly in response to corticosteroid.
Table 5. Multivariate analysis for the prediction of the
severity of liver disease.
Data F$3 versus F,3
P OR 95%CI
Alkaline phosphatase 0.1566 0.901 0.9556–1.0072
Bilirubin 0.3540 0.902 0.7273–1.1207
Prothrombin index 0.0142 0.675 0.4940–0.9245
Cell death marker 0.0497 0.991 0.9833–0.9999
Apoptotic marker 0.0211 1.032 1.0047–1.0607
Hyaluronate 0.0073 1.068 1.0181–1.1221
Patients were classified according to Fibrosis (F) ,3o r$3. Multivariate analysis
was performed using logistic regression.
doi:10.1371/journal.pone.0017599.t005
Figure 2. Levels of total, apoptotic and necrotic cells death
markers for diagnosis of advanced fibrosis (F$3) in 143
alcoholic patients. The area under the ROC curves are shown for
the performance of the total (CK18 total), apoptotic (CK18 fragment)
and necrotic (CK18 total-fragment) cell death markers for predicting
advanced fibrosis (F$3).
doi:10.1371/journal.pone.0017599.g002
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